Celgene Corporation (NASDAQ:CELG) to Present at UBS Global Life Sciences Conference September 23

Celgene Corporation (NASDAQ:CELG) will speak at the UBS Global Life Sciences Conference on Tuesday, September 23 at 8:00 am ET.  A webcast of the presentation will be available on the Investor Relations section of the company’s website at ir.celgene.com.

Celgene Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases.

The Company’s lead product is REVLIMID (lenalidomide) and THALOMID. REVLIMID was approved by the United States Food and Drug Administration (FDA), the European Commission, Swiss Agency for Therapeutic Products and Australian Therapeutic Goods Administration, for treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy.

THALOMID was approved by the FDA for treatment in combination with dexamethasone of patients with diagnosed multiple myeloma and is also approved for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of leprosy. In March 2008, Celgene Corporation completed the acquisition of Pharmion Corporation.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory.